Genmab — November 2018

[Sukkeralf]

Ja læste den i går Bulder og var enig i det der blev skrevet herinde - flot respons men besværligt og ej heller en attraktiv bivirkningsprofil. Umiddelbart tænker man jo ikke at den har mulighed helt fremme

[E_L]

@Sukkeralf:
https://ash.confex.com/ash/2018/webprogram/Paper115200.html

[Sukkeralf]

EL I have looked at that but there is no clinical responses - that was what I was looking for

[E_L]

no, could not find that either.

[peter12]

Ang BCMA og ASH https://www.biocentury.com/bc-extra/clinical-news/2018-11-01/bcma-race-heats-ash-abstracts-released

[E_L]

so either it disappoints, or it is a late breaker…

[Sukkeralf]

or just no new data

[E_L]

or that. But they had primary completion date in august, so i would expect something? and they were a big hit last ASH... we'll have to wait

[Legolas23]

Nyt why wait?

[Legolas23]

But

[Sukkeralf]

Also exciting to see data from
Pfizers BCMA CD3

[Sukkeralf]

a bit disappointed that we dont get any data from Janssen regarding BCMA/CD3 - they should be as far as Pfizer

[E_L]

havent seen pfizer's yet; they have some results?

[E_L]

@Lego i meant wait to see if they have a late breaker for GSK

[E_L]

looking at the JNJ trial, you are correct, they started a few months before Pfizer, and have a Primary Completion Date : November 1, 2018 …. (vs Pfizer June 2021)

[transalp]

Synes der er medvind på børsen sådan en fredag middag..

[Raun]

Tror AQR er i gang med at lukke deres short position....

[Raun]

¨

[AaBforever]

Dejligt..:-)

[JørgenVarnæs]

ja, det haster med at få den værdi op. GEN er en sitting duck